Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors
- K. Mody, A. Mansfield, L. Vemireddy, P. Nygren, Joachim Gulbo, M. Borad
- Investigational New Drugs
- 1 August 2019
VLX600 was reasonably well tolerated and, together with preclinical data, there is support for further efforts to explore its activity as single agent and in combination with drugs or radiation. Expand